Paul Bien

Paul Bien is a Scientific Advisor at August Therapeutics. Paul has also served as Vice President at Amplyx Pharmaceuticals, Inc., Project Management & Clinical Microbiology at Trius Therapeutics, Research Team Leader - Early Development at Pfizer, and Clinical Operations at Agouron Pharmaceuticals.

Paul has over 25 years of experience in the pharmaceutical industry. Paul has extensive experience in program management, clinical operations, and research and development. Paul has played a key role in the development and commercialization of several important drugs, including Trius’s Tedizolid (Sivextro), which was approved by the FDA in 2014 for the treatment of skin infections.

A native of California, Paul received their BS in Microbiology from UC Davis and their PhD in Molecular Biology from UC San Diego.

Paul Bien received their Masters of Science in Clinical Trial Design & Statistical Analysis from the University of Michigan. Paul also has a MS in Clinical Trial Design from the University of Michigan.